Combined systemic and intrapleural treatment of Aspergillus pulmonary empyema after invasive aspergillosis.
A 12-year-old immunocompromised boy was hospitalized because of invasive aspergillosis with lung and central nervous system involvement. He was treated with surgery and liposomal amphotericin B, but he developed a pulmonary empyema and a bronchopleural-cutaneous fistula. A catheter was placed through the fistula, and amphotericin B (up to 50 mg in 10 ml of 5% dextrose) was instilled daily into the pleural cavity for 45 days. Treatment was well-tolerated, and the empyema resolved completely, with no evidence of recurrence after 2 years of follow-up.
Baquero-Artigao
Fernando
F
Servicios de Enfermedades Infecciosas, Hospital Universitario Infantil La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain. fbaquero@teleline.es
García-Miguel
Maria Jesús
MJ
Hernández
Francisco
F
Hernández
Natalio
N
del Castillo
Fernando
F
D000666:Amphotericin B / Q000008:administration & dosage*; D001228:Aspergillosis / Q000150:complications / Q000175:diagnosis*; D002648:Child; D016724:Empyema, Pleural / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D005500:Follow-Up Studies; D016469:Fungemia / Q000150:complications / Q000175:diagnosis*; D006801:Humans; D016867:Immunocompromised Host; D007262:Infusions, Intravenous; D015552:Injections, Intralesional; D008279:Magnetic Resonance Imaging; D008297:Male; D018570:Risk Assessment; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000666:Amphotericin B